Clear Creek Financial Management LLC sells 207 shares of Johnson & Johnson (NYSE: JNJ)


Clear Creek Financial Management LLC reduced its stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 4.7% in Q1, according to the company in its latest filing with the Securities and Exchange Commission (SEC). The fund held 4,154 shares of the company after selling 207 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Johnson & Johnson were worth $736,000 when it last filed with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently changed their positions in the stock. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter worth about $26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson stock in Q4 worth $34,000. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson stock during Q1 for $38,000. Advocacy Wealth Management Services LLC increased its position in Johnson & Johnson by 41.4% in Q1. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC bought a new position in Johnson & Johnson stock during the fourth quarter valued at around $49,000. Institutional investors hold 68.78% of the company’s shares.

Johnson & Johnson trades up 0.2%

NYSE JNJ shares opened at $174.52 on Friday. The company has a market capitalization of $459.23 billion, a PE ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a debt ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company’s 50-day moving average price is $175.95 and its 200-day moving average price is $174.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last reported results on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company posted revenue of $24.02 billion for the quarter, versus a consensus estimate of $23.85 billion. During the same period last year, the company posted EPS of $2.48. The company’s revenue increased by 3.0% compared to the same quarter last year. On average, equity research analysts expect Johnson & Johnson to post EPS of 10.05 for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a dividend yield of 2.59%. Johnson & Johnson’s payout ratio is 65.79%.

Insider buying and selling

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. As a result of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other news, CAO Robert J. Decker sold 8,462 shares in a trade that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accountant now owns 15,473 shares of the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. The disclosure of this sale can be found here. 0.35% of the shares are currently held by company insiders.

Analyst upgrades and downgrades

A number of analysts have weighed in on JNJ shares recently. SVB Leerink lowered its price target on Johnson & Johnson from $200.00 to $194.00 in a Wednesday July 20 research note. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the company an “outperform” rating in a Wednesday, April 20 research note. Citigroup lowered its price target on Johnson & Johnson shares from $205.00 to $201.00 in a Wednesday, July 20 report. Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a Tuesday, April 12 report. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research rating. Four equity research analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.